LR

Addex Regains Nasdaq Listing Compliance

Retrieved on: 
Wednesday, November 8, 2023
SIX, Therapy, ADS, LR, Auction

53 LR

Key Points: 
  • 53 LR
    Geneva, Switzerland, November 8, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced it had received written notification from The Nasdaq Stock Market LLC (Nasdaq) that it has regained compliance with the minimum bid price requirement of $1.00 per ADS under Nasdaq Listing Rule 5550(a)(2) and currently meets all other applicable criteria for continued listing.
  • Addex announced on May 18, 2023 that it had been notified by Nasdaq that its ADSs were not in compliance with the minimum bid price rule.
  • To regain compliance, Addex was required to maintain a minimum closing bid price of $1.00 per ADS for at least 10 consecutive business days.
  • This requirement was met on November 3, 2023.

Spexis Announces Changes to the Executive Committee

Retrieved on: 
Wednesday, November 1, 2023
Knowledge, Railway Executive Committee, Trust, LR, Allschwil, Rare, Executive Committee, Therapy, Human resources, Management, Spexy Beast

Allschwil, Switzerland, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases and oncology, today announced that Hernan Levett, currently Chief Financial Officer, has decided to pursue a new career opportunity outside the company. He will continue to support the company as a strategic advisor on financial transactions and will depart the company effective December 1, 2023. Martin Jakobovic, currently Head of Finance, will succeed Hernan Levett as interim Chief Financial Officer joining the Executive Committee on December 1, 2023. Additionally, Muriel Fleming, currently Head of Human Resources, will assume additional responsibilities related to administration and facilities, as well as joining the Executive Committee of Spexis also on December 1, 2023.

Key Points: 
  • He will continue to support the company as a strategic advisor on financial transactions and will depart the company effective December 1, 2023.
  • Martin Jakobovic, currently Head of Finance, will succeed Hernan Levett as interim Chief Financial Officer joining the Executive Committee on December 1, 2023.
  • Additionally, Muriel Fleming, currently Head of Human Resources, will assume additional responsibilities related to administration and facilities, as well as joining the Executive Committee of Spexis also on December 1, 2023.
  • “I would like to thank Jeff, the board of directors, our shareholders, and the entire Spexis team for their trust, support, and commitment.

Basilea announces exclusive license and option agreement for potential first-in-class clinical-stage antibacterial agent

Retrieved on: 
Tuesday, October 31, 2023
KOSDAQ, Trial of the century, South Korea, MSSA, Bacteriophage, Biofilm, Intron, Gram-positive bacteria, Infection, Virus, Exercise, Biotechnology, A-DNA, Antimalarial medication, MRSA, LR, Bacteria, Korea, Patient, Death, Pharmaceutical industry, Vaccine, Basel, Allschwil

Tonabacase is a potential first-in-class clinical-stage antibacterial of the endolysin class.

Key Points: 
  • Tonabacase is a potential first-in-class clinical-stage antibacterial of the endolysin class.
  • Over the course of 2024, Basilea will investigate various hypotheses in a number of preclinical studies to determine the optimal future clinical development program for tonabacase.
  • Upon successful completion of the preclinical evaluation phase, Basilea will have the exclusive option to license tonabacase for further clinical development and commercialization.
  • This transaction has no impact on Basilea’s financial guidance for 2023, provided on August 15, 2023.

Geron IMerge Phase 3 Presentations at Upcoming ASH Annual Meeting Reinforce Significant Durability and Breadth of Effect of Imetelstat in Lower Risk MDS

Retrieved on: 
Thursday, November 2, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, International Prognostic Scoring System, IPSS, Survival, FDA, RUNX1, H. Lee Moffitt Cancer Center & Research Institute, VAF, Food, TP53, Thrombocytopenia, Literature, EZH2, MDS, European Medicines Agency, Regulation of tobacco by the U.S. Food and Drug Administration, Imetelstat, Society, ASXL1, SF3B1, Transfusion-dependent anemia, Geron Corporation, Risk, Abstract, TI, EMA, Corporation, LR, Anemia, ETV6, Patient, Neutropenia, Mutation, Pharmaceutical industry, Communications satellite, ASH

Four abstracts have been accepted for presentation at the 65th American Society of Hematology (ASH) Annual Meeting taking place from December 9-12 in San Diego, California and virtually.

Key Points: 
  • Four abstracts have been accepted for presentation at the 65th American Society of Hematology (ASH) Annual Meeting taking place from December 9-12 in San Diego, California and virtually.
  • “Additionally, our abstract showcasing a real-world data population level analysis of over 5,000 lower risk MDS patients adds to the significant literature suggesting a correlation between TI and improvement in survival.
  • This analysis suggests imetelstat has clinical activity in lower risk MDS patients independent of risk categories.
  • Achievement of durable TI was associated with improved survival, supporting the clinical benefit of achieving transfusion independence in lower risk MDS.

Labroots Announces Agenda for its 14th Annual Clinical Diagnostics & Research Online Event - held on November 8th, 2023

Retrieved on: 
Monday, November 6, 2023
Linda, TBI, Q&A, Pathology, Medical laboratory, Clinical professor, Workplace, Research, Sartorius, Dietary supplement, Mass spectrometry, Ortho Clinical Diagnostics, Roche, Networking hardware, Medicine, Labroots, Greeting, LR, Personalized medicine, Melissa Chaty, Thermo Fisher Scientific, Diversity, Lab, Patient, Mayo Clinic, Medical device, Nursing, News, Clinical

YORBA LINDA, Calif., Nov. 6, 2023 /PRNewswire-PRWeb/ -- Labroots, the leading scientific social networking website offering premier, interactive virtual and hybrid events and webinars, today announced its 14th annual event in the Clinical Diagnostics & Research Virtual Event Series scheduled on November 8, 2023. This event will continue its long-standing commitment to advance clinical diagnostics, novel research and medicine, and to align research scholars, clinicians, top scientists, healthcare professionals and experts from leading academia and industry institutions under a virtual roof on a global basis.

Key Points: 
  • YORBA LINDA, Calif., Nov. 6, 2023 /PRNewswire-PRWeb/ -- Labroots , the leading scientific social networking website offering premier, interactive virtual and hybrid events and webinars, today announced its 14th annual event in the Clinical Diagnostics & Research Virtual Event Series scheduled on November 8, 2023.
  • Attendees will also see multiple panels and presentations from key industry sponsors including, Sartorius, Thermo Fisher Scientific, and Roche Diagnostics.
  • Use the hashtag #LRclinical to follow the conversation and connect with other members of the global Clinical & Molecular Dx Community!
  • Join our Clinical & Molecular Dx Interest Group on LinkedIn to connect with us, and the wider professional community!

Aviation Capital Group Appoints Vicente Alava Pons Managing Director of Aircraft Financing Solutions

Retrieved on: 
Wednesday, November 1, 2023
Professional Services, Air, Aerospace, Transport, Manufacturing, Finance, Asset Management, Aircraft, Capital Group Companies, MUFG Bank, EVP, AFS, Economics, ACG, University of Duisburg-Essen, Pons, Workplace, DVB Bank, Growth, LR, University, Aviation, Airline

Aviation Capital Group LLC (ACG) today announced that Vicente Alava Pons has joined the company as a Managing Director on the Aircraft Financing Solutions (AFS) team.

Key Points: 
  • Aviation Capital Group LLC (ACG) today announced that Vicente Alava Pons has joined the company as a Managing Director on the Aircraft Financing Solutions (AFS) team.
  • Pons will be based in Europe, supporting the growth of ACG’s AFS business by developing and structuring new creative financing solutions for airlines and lenders worldwide.
  • “Vicente brings innovative perspectives that will play a pivotal role in steering our company towards continued growth and success.
  • "I am excited to join a well-established and world-leading aircraft lessor like ACG and contribute to expanding the Aircraft Financing Solutions group’s business potential,” said Pons.

Logitech Appoints Hanneke Faber as Chief Executive Officer

Retrieved on: 
Monday, October 30, 2023
Entertainment, Consumer Electronics, Technology, Audio, Video, Software, Electronic Games, Hardware, Silicon, Innovation, Logitech, Engineering, Multimedia, Procter & Gamble, Growth, Unilever, Hanneke, LR, SIX Swiss Exchange, SIX, Culture, Ahold Delhaize, Management

53 LR — Logitech International (SIX: LOGN) (Nasdaq: LOGI) announced today that, following an extensive, global search, its board of directors has appointed Hanneke Faber as the Company’s new chief executive officer.

Key Points: 
  • 53 LR — Logitech International (SIX: LOGN) (Nasdaq: LOGI) announced today that, following an extensive, global search, its board of directors has appointed Hanneke Faber as the Company’s new chief executive officer.
  • View the full release here: https://www.businesswire.com/news/home/20231030313893/en/
    “We are delighted to welcome Hanneke as our new chief executive officer,” said Wendy Becker, Logitech’s chairperson of the board.
  • “Hanneke is an exceptional business executive with proven leadership experience at a global scale.
  • He will continue as interim CEO until December 1, 2023, before resuming his board responsibilities, including leading the Technology and Innovation Committee.”
    “I am deeply honored to join Logitech,” said Hanneke Faber.

Santhera Receives U.S. FDA Approval of AGAMREE® (vamorolone) for the Treatment of Duchenne Muscular Dystrophy

Retrieved on: 
Friday, October 27, 2023
FDA, Standard of care, Food, CHMP, European Commission, Hope, Behavior, Physician, European Medicines Agency, News, Doctor of Philosophy, EC, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Catalyst Pharmaceuticals, Research, Vamorolone, PPMD, Civil service commission, Disease, Duchenne muscular dystrophy, LR, NDA, DMD, European, Patient, Pharmaceutical industry, Catalysis, Duchenne, EU

“We are delighted to secure FDA approval which comes just weeks after the positive opinion from the CHMP of the European Medicines Agency.

Key Points: 
  • “We are delighted to secure FDA approval which comes just weeks after the positive opinion from the CHMP of the European Medicines Agency.
  • This is a hugely important moment for DMD patients who need an efficacious and well-tolerated therapy for this debilitating condition,” said Dario Eklund, CEO of Santhera.
  • “Steroids are considered standard of care for Duchenne, due to their valuable role in slowing disease progression.
  • Subject to approval, AGAMREE will be the only medicinal product fully approved in both territories, the EU and the U.S., for the treatment of DMD.

Logitech Files Quarterly Report on Form 10-Q

Retrieved on: 
Thursday, October 26, 2023
Consumer Electronics, Technology, Mobile, Wireless, Audio, Video, Software, Hardware, Fiscal, SIX Swiss Exchange, Logitech, SIX, File, LR, Cryptocurrency

SIX Swiss Exchange Ad hoc announcement pursuant to Art.

Key Points: 
  • SIX Swiss Exchange Ad hoc announcement pursuant to Art.
  • 53 LR — Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced that on October 26, 2023, it filed with the U.S. Securities and Exchange Commission (SEC) its Quarterly Report on Form 10-Q for the second quarter of Fiscal Year 2024.
  • The filing is available on the SEC's website at www.sec.gov and Logitech's website at http://ir.logitech.com .

Addex Completes ADS Ratio Change

Retrieved on: 
Friday, October 20, 2023
Sale, Tax, Ratio, American depositary receipt, ADS, LR, SIX, Therapy, Security (finance)

The ratio will change from one (1) ADS to six (6) ordinary shares to a new ADS ratio of one (1) ADS to one hundred and twenty (120) ordinary shares (the “Ratio Change”).

Key Points: 
  • The ratio will change from one (1) ADS to six (6) ordinary shares to a new ADS ratio of one (1) ADS to one hundred and twenty (120) ordinary shares (the “Ratio Change”).
  • For the Company’s ADS holders, the change in the ADS ratio has the same effect as a one (1) for twenty (20) reverse ADS split and is intended to enable the Company to regain compliance with the Nasdaq minimum bid price requirement.
  • The Ratio Change has no impact on the Company’s underlying ordinary shares, and no ordinary shares will be issued or cancelled in connection with the Ratio Change.
  • The Ratio Change affects all ADS holders uniformly and will not alter any ADS holder’s percentage interest in the company’s equity, except to the extent that the Ratio Change would have resulted in an ADS holder owning fractional ADS.